Bone biomarkers in haemodialysis patients: Bone alkaline phosphatase or ß-Crosslaps?;Quels marqueurs osseux chez les patients hémodialysés : phosphatases alcalines osseuses ou ß-CrossLaps ?

Nephrologie et Therapeutique

Volumn 9, Issue 3, 2013, Pages 154-159

  Jean, Guillaume ^a   Souberbielle, Jean Claude ^b   Granjon, Samuel ^c   Lorriaux, Christie ^a   Hurot, Jean Marc ^a   Mayor, Brice ^a   Deleaval, Patrik ^a   Chazot, Charles ^a  

^a Nephrocare Tassin Charcot   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Laboratoire du Grand Vallon   (France)

Author keywords

Bone markers; Bone specific alkaline phosphatase; Hemodialysis; Parathyroid hormone; CrossLaps; Total alkaline phosphatases

Indexed keywords

ALKALINE PHOSPHATASE; PARATHYROID HORMONE;

AGED; ARTICLE; BONE; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE;

EID: 84880234607     PISSN: 17697255     EISSN: 18729177     Source Type: Journal    
DOI: 10.1016/j.nephro.2013.02.006     Document Type: Article

References (29)

1. KDIGO C-M, Work Group KDIGO. Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone disorder (CKD-MBD). Kidney Int 2009;76(Suppl. 113):S1-30.
2. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008;19(9): 1827-35.
3. Jean G, Bresson E, Lorriaux C, Mayor B, Hurot JM, Deleaval P, et al. Increased levels of serum parathyroid hormone and fibroblast growth factor-23 are the main factors associated with the progression of vascular calcification in longhour hemodialysis patients. Nephron Clin Pract 2012;120(3):c132-8.
4. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995;26(4): 622-31.
5. Jean G, Souberbielle JC, Zaoui E, Lorriaux C, Mayor B, Hurot JM, et al. Total and bone-specific alkaline phosphatases in haemodialysis patients with chronic liver disease. Clin Biochem 2012;45(6): 436-9.
6. Okuno S, Inaba M, Kitatani K, Ishimura E, Yamakawa T, Nishizawa Y. Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporos Int 2005;16(5): 501-9.
7. Reichel H, Roth HJ, Schmidt-Gayk H. Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients. Nephron 2004;98(4):c112-8.
8. Manghat P, Souleimanova I, Cheung J, Wierzbicki AS, Harrington DJ, Shearer MJ, et al. Association of bone turnover markers and arterial stiffness in predialysis chronic kidney disease (CKD). Bone 2011;48(5): 1127-32.
9. Park JC, Kovesdy CP, Duong U, Streja E, Rambod M, Nissenson AR, et al. Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodialys Int 2010;14(2): 182-92.
10. Ueda M, Inaba M, Okuno S, Maeno Y, Ishimura E, Yamakawa T, et al. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Life Sci 2005;77(10): 1130-9.
11. Barreto FC, Barreto DV, Moyses RM, Neves KR, Canziani ME, Draibe SA, et al. K/ DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008;73(6): 771-7.
12. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000;58(2): 753-61.
13. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006;70(2): 345-50.
14. Jovanovich A, Chonchol M, Cheung AK, Kaufman JS, Greene T, Roberts WL, et al. Racial differences in markers of mineral metabolism in advanced chronic kidney disease. Clin J Am Soc Nephrol 2012;7(4): 640-7.
15. Ballanti P, Wedard BM, Bonucci E. Frequency of adynamic bone disease and aluminum storage in Italian uraemic patients-retrospective analysis of 1429 iliac crest biopsies. Nephrol Dial Transplant 1996;11(4): 663-7.
16. Kazama JJ, Omori K, Yamamoto S, Ito Y, Maruyama H, Narita I, et al. Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism. Ther Apher Dial 2006;10(3): 262-6.
17. Jean G, Chazot C, Charra B. 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin Nephrol 2007;68(1): 63-4.
18. Sanchez C, Lopez-Barea F, Sanchez-Cabezudo J, Bajo A, Mate A, Martinez E, et al. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 2004;19(6): 1587-93.
19. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(4 Suppl 3): 1-201.
20. Epstein S, Traberg H, Raja R, Poser J. Serum and dialysate osteocalcin levels in hemodialysis and peritoneal dialysis patients and after renal transplantation. J Clin Endocrinol Metab 1985;60(6): 1253-6.
21. Shantouf R, Kovesdy CP, Kim Y, Ahmadi N, Luna A, Luna C, et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2009;4(6): 1106-14.
22. Beddhu S, Ma X, Baird B, Cheung AK, Greene T. Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. Clin J Am Soc Nephrol 2009;4(11): 1805-10.
23. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999;55(6): 2141-56.
24. Sardiwal S, Gardham C, Coleman AE, Stevens PE, Delaney MP, Lamb EJ. Bonespecific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int 2012;82(1): 100-5.
25. Couttenye MM, D'Haese PC, Van Hoof VO, Lemoniatou E, Goodman W, Verpooten GA, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996;11(6): 1065-72.
26. Iimori S, Mori Y, Akita W, Kuyama T, Takada S, Asai T, et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients-a single-center cohort study. Nephrol Dial Transplant 2012;27(1): 345-51.
27. Damera S, Raphael KL, Baird BC, Cheung AK, Greene T, Beddhu S. Serum alkaline phosphatase levels associate with elevated serum C-reactive protein in chronic kidney disease. Kidney Int 2011;79(2): 228-33.
28. Drechsler C, Verduijn M, Pilz S, Krediet RT, Dekker FW, Wanner C, et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 2011;6(7): 1752-9.
29. Waller S, Ridout D, Rees L. Effect of haemodialysis on markers of bone turnover in children. Pediatr Nephrol 2007;22(4): 586-92.